Physician profile
Keri Evans
NPI 1811351554
$3,244.48
in general payments reported to CMS, 2019-2025
25 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $455 · 2023: $331 · 2024: $489 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.58 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $633.96 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $370.78 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $360.46 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.55 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $171.10 | 2021-2025 | |
| Astellas Pharma US INC | $156.95 | 2021-2024 | Veozah |
| Abbvie INC. | $153.98 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.91 | 2022-2025 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $135.45 | 2021-2022 | |
| Lilly USA, LLC | $133.53 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $107.37 | 2021-2025 | Rexulti |
| Amgen INC. | $104.14 | 2024-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $101.79 | 2022-2025 | |
| Corcept Therapeutics | $61.23 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $53.60 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47.22 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $46.56 | 2025 | Quviviq |
| Ardelyx, INC. | $26.70 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $20.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.33 | 2025 | Eliquis |
| Sumitomo Pharma America, INC. | $18.16 | 2023 | Gemtesa |
| Antares Pharma, INC. | $18.02 | 2025 | Xyosted |
| Verona Pharma, INC. | $15.18 | 2025 | Ohtuvayre |
| Medtronic, INC. | $13.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.